Avidity Biosciences, Inc.

RNA

US05370A1088

Pharmaceuticals

Delayed Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
37.21 ^USD	-4.10%		-6.77%	+311.16%

Jul. 01	Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 3000 Value Index	CI
Jul. 01	Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2500 Value Index	CI

Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 3000 Value Index

July 30, 2024

Latest news about Avidity Biosciences, Inc.

Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 3000 Value Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2500 Value Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell 3000E Growth Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell 3000 Growth Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 2000 Value Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell 2000 Growth Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell Microcap Value Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 3000E Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell 3000E Value Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) dropped from Russell Microcap Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell 2500 Growth Index	Jun. 30	CI
Avidity Biosciences, Inc.(NasdaqGM:RNA) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Avidity Biosciences Insider Sold Shares Worth $1,255,040, According to a Recent SEC Filing	Jun. 21	MT
Wells Fargo Raises Price Target on Avidity Biosciences to $75 From $50, Maintains Overweight Rating	Jun. 14	MT
Avidity Biosciences Prices $400.9 Million Offering of Shares	Jun. 14	MT
Avidity Biosciences Plans $300 Million Common Stock Offering	Jun. 12	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Jun. 12	MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon	Jun. 12	MT
Avidity Biosciences Shares Jump as Muscle Disease Therapy Shows Promising Early Results	Jun. 12	MT
Sector Update: Health Care	Jun. 12	MT
Top Midday Gainers	Jun. 12	MT
Chardan Raises Price Target on Avidity Biosciences to $45 From $33, Maintains Buy Rating	Jun. 12	MT
Avidity Biosciences's Muscle Disease Therapy Shows Promising Early Results -- Shares Surge Pre-Bell	Jun. 12	MT
Transcript : Avidity Biosciences, Inc. - Shareholder/Analyst Call	Jun. 12
Avidity Biosciences, Inc. Announces Positive Initial AOC 1020 Data from the Phase 1/2 FORTITUDE Trial Demonstrating Greater Than 50% Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy	Jun. 12	CI

Chart Avidity Biosciences, Inc.

Duration

Period

More charts

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Avidity Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37.21 USD

Average target price

61.56 USD

Spread / Average Target

+65.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
AVIDITY BIOSCIENCES, INC.	+311.16%	3.95B
CSL LIMITED	+3.79%	95.71B
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	41.64B
BIOGEN INC.	-13.20%	32.7B
UCB	+79.53%	28.65B
BIOMARIN PHARMACEUTICAL INC.	-16.02%	15.38B
INCYTE CORPORATION	-8.17%	12.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-13.35%	11.47B
ALTEOGEN INC.	+160.91%	9.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-56.29%	9.07B

Biopharmaceuticals